TherapeuticsMD, Inc. — Director's Dealing 2021

Aug 31, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TherapeuticsMD, Inc. (TXMD)
CIK: 0000025743
Period of Report: 2021-08-31

Reporting Person: O'Dowd Hugh (President)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-08-31	Performance Stock Units	$0.00	A	2750000	Acquired		Common Stock (2750000)	Direct
2021-08-31	Restricted Stock Units	$0.00	A	2750000	Acquired		Common Stock (2750000)	Direct

Footnotes

F1: The performance stock units (PSUs) vest on August 31, 2024 based on the market capitalization of the issuer, which will be tested annually over three years beginning August 31, 2022 and are subject to the continuous service of the reporting person with the issuer. The number of PSUs listed is the maximum number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and maximum number of PSUs, depending on the milestones achieved. Each PSU represents a contingent right to receive one share of common stock of the issuer.

F2: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning August 31, 2022, becoming fully vested on August 31, 2024, subject in each case to the continued service of the reporting person with the issuer.